BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/16/2024 10:39:01 AM | Browse: 226 | Download: 1198
Publication Name World Journal of Diabetes
Manuscript ID 95123
Country China
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pharmacology & Pharmacy
Manuscript Type Basic Study
Article Title Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation
Manuscript Source Unsolicited Manuscript
All Author List Yan Shang, Cai-Yun Yan, Hui Li, Na Liu and Hui-Feng Zhang
ORCID
Author(s) ORCID Number
Hui-Feng Zhang http://orcid.org/0009-0004-1197-3307
Funding Agency and Grant Number
Corresponding Author Hui-Feng Zhang, MM, Doctor, Doctor, Department of Nephrology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, No. 99 Longcheng Street, Xiaodian District, Taiyuan 030032, Shanxi Province, China. zhanghuifeng1977@163.com
Key Words Tiliroside; Diabetic nephropathy; Antioxidant; Diabetes mellitus; Oxidative stress; Inflammation
Core Tip Tiliroside (Til) demonstrates potent protective effects against diabetic nephropathy (DN) in Sprague Dawley rats, alongside glibenclamide. Through attenuating oxidative stress, inflammation, and fibrosis, Til treatment significantly improves renal function and reduces biochemical markers associated with DN. Molecular docking analysis reveals its potential inhibition of key markers linked to the disease. These findings underscore Til's promising role as a therapeutic agent for DN, suggesting avenues for future drug development.
Publish Date 2024-10-16 10:39
Citation

Shang Y, Yan CY, Li H, Liu N, Zhang HF. Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation. World J Diabetes 2024; 15(11): 2220-2236

URL https://www.wjgnet.com/1948-9358/full/v15/i11/2220.htm
DOI https://dx.doi.org/10.4239/wjd.v15.i11.2220
Full Article (PDF) WJD-15-2220-with-cover.pdf